1- Sharifi, A.H., Haj-Sheykholeslami, A., Poustchi, H., (...), Malekzadeh, R., Nateghi, A

Efficacy of locally manufactured sofosbuvir and daclatasvir (Sovodak) in combination with ribavirin in treating patients with chronic hepatitis C and Cirrhosis in Iran - Preliminary report.

Govaresh 2016.21(2), pp. 93-97


2- Merat, S., Sharifi, A.H., Haj-Sheykholeslami, A., (...), Alavian, S.M., Malekzadeh, R.

The efficacy of 12weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3.

Hepatitis Monthly.201717(1),e44564, pp. 1-4


3- Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, Zamini H, Merat S, Malekzadeh R, Sharfi AH

Pegaferon in hepatitis C: Results of a Multicenter Study.
Middle East J Dig Dis. 2011 Sep;3(2):110-4


4- Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, ... , Malekzadeh R

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline.

Hepat Mon. 2016 Aug 13;16 (8):e40959. Review